The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Sonrotoclax plus dexamethasone in patients with R/R myeloma harboring t(11;14): a Phase Ib/II trial
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, introduces an ongoing Phase Ib/II study (NCT04973605) investigating the safety and efficacy of sonrotoclax, a novel BCL2 inhibitor, in combination with dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14). Dr Dhakal discusses the dose escalation portion of the trial and comments on the preliminary safety and efficacy of this therapeutic regimen. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
